IFNB1 and tropical spastic paraparesis: Moreover, clinical studies using IFN-β therapy in HAM/TSP patients have demonstrated benefits in reducing HTLV-1 mRNA load and the number of pathogenic CD8+ T cells, as well as minimizing disease progression during therapy [51].